Free Trial

Kumaraguru Raja Analyst Performance

Analyst at Brookline Capital Markets

Kumaraguru Raja is a stock analyst at Brookline Capital Markets in the healthcare sector, covering 11 publicly traded companies. Over the past year, Kumaraguru Raja has issued 1 stock ratings, including and buy recommendations. While full access to Kumaraguru Raja's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kumaraguru Raja's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
15 Last 9 Years
Buy Recommendations
100.00% 14 Buy Ratings
Companies Covered
11 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%14 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
11 companies

Kumaraguru Raja, an analyst at Brookline Capital Markets, currently covers 11 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
11 companies
100.0%

Kumaraguru Raja of Brookline Capital Markets specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
6 companies
54.5%
BIOTECHNOLOGY
5 companies
45.5%

Kumaraguru Raja's Ratings History at Brookline Capital Markets

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
10/7/2026Initiated Coverage$1.25Buy
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
8/28/2025Set Price Target$4.28$8.00
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
8/12/2025Upgrade$7.35$75.00Buy